This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Almeida O.P., Yeap B.B., Hankey G.J., Jamrozik K., Flicker L.: Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch. Gen. Psychiatry, 2008; 65: 283–289AlmeidaO.P.YeapB.B.HankeyG.J.JamrozikK.FlickerL.Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older menArch. Gen. Psychiatry20086528328910.1001/archgenpsychiatry.2007.3318316674Search in Google Scholar
Araujo A.B., O’Donnell A.B., Brambilla D.J., Simpson W.B., Longcope C., Matsumoto A.M., McKinlay J.B.: Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab., 2004; 89: 5920–5926AraujoA.B.O’DonnellA.B.BrambillaD.J.SimpsonW.B.LongcopeC.MatsumotoA.M.McKinlayJ.B.Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging StudyJ. Clin. Endocrinol. Metab.2004895920592610.1210/jc.2003-03171915579737Search in Google Scholar
Baillargeon J., Urban R.J., Morgentaler A., Glueck C.J., Baillargeon G., Sharma G., Kuo Y.F..: Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin. Proc., 2015; 90: 1038–1045BaillargeonJ.UrbanR.J.MorgentalerA.GlueckC.J.BaillargeonG.SharmaG.KuoY.F..Risk of venous thromboembolism in men receiving testosterone therapyMayo Clin. Proc.2015901038104510.1016/j.mayocp.2015.05.01226205547Search in Google Scholar
Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano G.M.: Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol., 2009; 54: 919–927CaminitiG.VolterraniM.IellamoF.MarazziG.MassaroR.MiceliM.MammiC.PiepoliM.FiniM.RosanoG.M.Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized studyJ. Am. Coll. Cardiol.20095491992710.1016/j.jacc.2009.04.07819712802Search in Google Scholar
Chao J.K., Hwang T.I., Ma M.C., Kuo W.H., Liu J.H., Chen Y.P., Lin Y.C.: A survey of obesity and erectile dysfunction of men conscripted into the military in Taiwan. J. Sex. Med., 2011; 8: 1156–1163ChaoJ.K.HwangT.I.MaM.C.KuoW.H.LiuJ.H.ChenY.P.LinY.C.A survey of obesity and erectile dysfunction of men conscripted into the military in TaiwanJ. Sex. Med.201181156116310.1111/j.1743-6109.2010.02181.x21269394Search in Google Scholar
Corona G., Mannucci E., Fisher A.D., Lotti F., Petrone L., Balercia G., Bandini E., Forti G., Maggi M.: Low levels of androgens in men with erectile dysfunction and obesity. J. Sex. Med., 2008; 5: 2454–2463CoronaG.MannucciE.FisherA.D.LottiF.PetroneL.BalerciaG.BandiniE.FortiG.MaggiM.Low levels of androgens in men with erectile dysfunction and obesityJ. Sex. Med.200852454246310.1111/j.1743-6109.2008.00856.x18494771Search in Google Scholar
Corona G., Rastrelli G., Monami M., Melani C., Balzi D., Sforza A., Forti G., Mannucci E., Maggi M.: Body mass index regulates hypogonadism-associated CV risk: Results from a cohort of subjects with erectile dysfunction. J. Sex. Med., 2011; 8: 2098–2105CoronaG.RastrelliG.MonamiM.MelaniC.BalziD.SforzaA.FortiG.MannucciE.MaggiM.Body mass index regulates hypogonadism-associated CV risk: Results from a cohort of subjects with erectile dysfunctionJ. Sex. Med.201182098210510.1111/j.1743-6109.2011.02292.x21561538Search in Google Scholar
Coviello A.D., Matsumoto A.M., Bremner W.J., Herbst K.L., Amory J.K., Anawalt B.D., Sutton P.R., Wright W.W., Brown T.R., Yan X., Zirkin B.R., Jarow J.P.: Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J. Clin. Endocrinol. Metab., 2005; 90: 2595–2602CovielloA.D.MatsumotoA.M.BremnerW.J.HerbstK.L.AmoryJ.K.AnawaltB.D.SuttonP.R.WrightW.W.BrownT.R.YanX.ZirkinB.R.JarowJ.P.Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppressionJ. Clin. Endocrinol. Metab.2005902595260210.1210/jc.2004-080215713727Search in Google Scholar
Crum-Cianflone N.F., Bavaro M., Hale B., Amling C., Truett A., Brandt C., Pope B., Furtek K., Medina S., Wallace M.R.: Erectile dys-function and hypogonadism among men with HIV. AIDS Patient Care STDS, 2007; 21: 9–19Crum-CianfloneN.F.BavaroM.HaleB.AmlingC.TruettA.BrandtC.PopeB.FurtekK.MedinaS.WallaceM.R.Erectile dys-function and hypogonadism among men with HIVAIDS Patient Care STDS20072191910.1089/apc.2006.007117263654Search in Google Scholar
Dohle G.R., Arver S., Bettocchi C., Jones T.H., Kliesch S.: European association of urology guidelines on male hypogonadism: The 2018 update. https://uroweb.org/guideline/male-hypogonadism/ (05.02.2020)DohleG.R.ArverS.BettocchiC.JonesT.H.KlieschS.European association of urology guidelines on male hypogonadism: The 2018 updatehttps://uroweb.org/guideline/male-hypogonadism/ (05.02.2020)Search in Google Scholar
Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., Fraumeni J.F.Jr, Hoover R.N.: Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 2014; 9: e85805FinkleW.D.GreenlandS.RidgewayG.K.AdamsJ.L.FrascoM.A.CookM.B.FraumeniJ.F.JrHooverR.N.Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in menPLoS One20149e8580510.1371/journal.pone.0085805390597724489673Search in Google Scholar
Ford A.H., Yeap B.B., Flicker L., Hankey G.J., Chubb S.A., Handelsman D.J., Golledge J., Almeida O.P.: Prospective longitudinal study of testosterone and incident depression in older men: The Health In Men Study. Psychoneuroendocrinology, 2016; 64: 57–65FordA.H.YeapB.B.FlickerL.HankeyG.J.ChubbS.A.HandelsmanD.J.GolledgeJ.AlmeidaO.P.Prospective longitudinal study of testosterone and incident depression in older men: The Health In Men StudyPsychoneuroendocrinology201664576510.1016/j.psyneuen.2015.11.01226615472Search in Google Scholar
Francomano D., Greco E.A., Lenzi A., Aversa A.: CAG repeat testing of androgen receptor polymorphism: Is this necessary for the best clinical management of hypogonadism? J. Sex. Med., 2013; 10: 2373–2381FrancomanoD.GrecoE.A.LenziA.AversaA.CAG repeat testing of androgen receptor polymorphism: Is this necessary for the best clinical management of hypogonadism?J. Sex. Med.2013102373238110.1111/jsm.1226823844628Search in Google Scholar
Garvey W.T., Mechanick J.I., Brett E.M., Garber A.J., Hurley D.L., Jastreboff A.M., Nadolsky K., Pessah-Pollack R., Plodkowski R., Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines: Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr. Pract., 2016; 22: 1–203GarveyW.T.MechanickJ.I.BrettE.M.GarberA.J.HurleyD.L.JastreboffA.M.NadolskyK.Pessah-PollackR.PlodkowskiR.Reviewers of the AACE/ACE Obesity Clinical Practice GuidelinesAssociation of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with ObesityEndocr. Pract.201622120310.4158/EP161365.GL27219496Search in Google Scholar
Gianatti E.J., Dupuis P., Hoermann R., Zajac J.D., Grossmann M.: Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab., 2014; 99: 3821–3828GianattiE.J.DupuisP.HoermannR.ZajacJ.D.GrossmannM.Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trialJ. Clin. Endocrinol. Metab.2014993821382810.1210/jc.2014-187224978674Search in Google Scholar
Goodman N., Guay A., Dandona P., Dhindsa S., Faiman C., Cunningham G.R., AACE Reproductive Endocrinology Scientific Committee: American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular risk. Endocr. Pract., 2015; 21: 1066–1073GoodmanN.GuayA.DandonaP.DhindsaS.FaimanC.CunninghamG.R.AACE Reproductive Endocrinology Scientific CommitteeAmerican Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of testosterone and cardiovascular riskEndocr. Pract.2015211066107310.4158/EP14434.PS26355962Search in Google Scholar
Halabi S., Collins E.G., Thorevska N., Tobin M.J., Laghi F.: Relationship between depressive symptoms and hypogonadism in men with COPD. COPD, 2011; 8: 346–353HalabiS.CollinsE.G.ThorevskaN.TobinM.J.LaghiF.Relationship between depressive symptoms and hypogonadism in men with COPDCOPD2011834635310.3109/15412555.2011.59446521774576Search in Google Scholar
Hall S.A., Esche G.R., Araujo A.B., Travison T.G., Clark R.V., Williams R.E., McKinlay J.B.: Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J. Clin. Endocrinol. Metab., 2008; 93: 3870–3877HallS.A.EscheG.R.AraujoA.B.TravisonT.G.ClarkR.V.WilliamsR.E.McKinlayJ.B.Correlates of low testosterone and symptomatic androgen deficiency in a population-based sampleJ. Clin. Endocrinol. Metab.2008933870387710.1210/jc.2008-0021257965218664536Search in Google Scholar
Isidori A.M., Buvat J., Corona G., Goldstein I., Jannini E.A., Lenzi A., Porst H., Salonia A., Traish A.M., Maggi M.: A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment – A systematic review. Eur. Urol., 2014; 65: 99–112IsidoriA.M.BuvatJ.CoronaG.GoldsteinI.JanniniE.A.LenziA.PorstH.SaloniaA.TraishA.M.MaggiM.A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment – A systematic reviewEur. Urol.2014659911210.1016/j.eururo.2013.08.04824050791Search in Google Scholar
Jones T.H., Arver S., Behre H.M., Buvat J., Meuleman E., Moncada I., Morales A.M., Volterrani M., Yellowlees A., Howell J.D., Channer K.S., TIMES2 Investigators.: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care, 2011; 34: 828–837JonesT.H.ArverS.BehreH.M.BuvatJ.MeulemanE.MoncadaI.MoralesA.M.VolterraniM.YellowleesA.HowellJ.D.ChannerK.S.TIMES2 InvestigatorsTestosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study)Diabetes Care20113482883710.2337/dc10-1233306403621386088Search in Google Scholar
Kamischke A., Kemper D.E., Castel M.A., Lüthke M., Rolf C., Behre H.M., Magnussen H., Nieschlag E.: Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur. Respir. J., 1998; 11: 41–45KamischkeA.KemperD.E.CastelM.A.LüthkeM.RolfC.BehreH.M.MagnussenH.NieschlagE.Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapyEur. Respir. J.199811414510.1183/09031936.98.110100419543268Search in Google Scholar
Kaplan S.A., Lee J.Y., O’Neill E.A., Meehan A.G., Kusek J.W.: Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male, 2013; 16: 169–172KaplanS.A.LeeJ.Y.O’NeillE.A.MeehanA.G.KusekJ.W.Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasiaAging Male20131616917210.3109/13685538.2013.84478624134648Search in Google Scholar
Kelsey T.W., Li L.Q., Mitchell R.T., Whelan A., Anderson R.A., Wallace W.H.: A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 years. PLoS One, 2014; 9: e109346KelseyT.W.LiL.Q.MitchellR.T.WhelanA.AndersonR.A.WallaceW.H.A validated age-related normative model for male total testosterone shows increasing variance but no decline after age 40 yearsPLoS One20149e10934610.1371/journal.pone.0109346419017425295520Search in Google Scholar
Kohn T.P., Louis M.R., Pickett S.M., Lindgren M.C., Kohn J.R., Pastuszak A.W., Lipshultz L.I.: Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy. Fertil. Steril., 2017; 107: 351–357KohnT.P.LouisM.R.PickettS.M.LindgrenM.C.KohnJ.R.PastuszakA.W.LipshultzL.I.Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapyFertil. Steril.201710735135710.1016/j.fertnstert.2016.10.004529227627855957Search in Google Scholar
Malkin C.J., Pugh P.J., West J.N., van Beek E.J., Jones T.H., Channer K.S.: Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur. Heart J., 2006; 27: 57–64MalkinC.J.PughP.J.WestJ.N.van BeekE.J.JonesT.H.ChannerK.S.Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trialEur. Heart J.200627576410.1093/eurheartj/ehi44316093267Search in Google Scholar
Martens H.F., Sheets P.K., Tenover J.S., Dugowson C.E., Bremner W.J., Starkebaum G.: Decreased testosterone levels in men with rheumatoid arthritis: Effect of low dose prednisone therapy. J. Rheumatol., 1994; 21: 1427–1431MartensH.F.SheetsP.K.TenoverJ.S.DugowsonC.E.BremnerW.J.StarkebaumG.Decreased testosterone levels in men with rheumatoid arthritis: Effect of low dose prednisone therapyJ. Rheumatol.19942114271431Search in Google Scholar
Mateo L., Nolla J.M., Bonnin M.R., Navarro M.A., Roig-Escofet D.: Sex hormone status and bone mineral density in men with rheumatoid arthritis. J. Rheumatol., 1995; 22: 1455–1460MateoL.NollaJ.M.BonninM.R.NavarroM.A.Roig-EscofetD.Sex hormone status and bone mineral density in men with rheumatoid arthritisJ. Rheumatol.19952214551460Search in Google Scholar
Mazzola C.R., Katz D.J., Loghmanieh N., Nelson C.J., Mulhall J.P..: Predicting biochemical response to clomiphene citrate in men with hypogonadism. J. Sex. Med. 2014; 11: 2302–2307MazzolaC.R.KatzD.J.LoghmaniehN.NelsonC.J.MulhallJ.P..Predicting biochemical response to clomiphene citrate in men with hypogonadismJ. Sex. Med.2014112302230710.1111/jsm.1259224902614Search in Google Scholar
Morgentaler A., Miner M.M., Caliber M., Guay A.T., Khera M., Traish A.M.: Testosterone therapy and cardiovascular risk: Advances and controversies. Mayo Clin. Proc., 2015; 90: 224–251MorgentalerA.MinerM.M.CaliberM.GuayA.T.KheraM.TraishA.M.Testosterone therapy and cardiovascular risk: Advances and controversiesMayo Clin. Proc.20159022425110.1016/j.mayocp.2014.10.01125636998Search in Google Scholar
Morgentaler A., Zitzmann M., Traish A.M., Fox A.W., Jones T.H., Maggi M., Arver S., Aversa A., Chan J.C., Dobs A.S., Hackett G.I., Hellstrom W.J., Lim P., Lunenfeld B., Mskhalaya G. i wsp.: Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutions. Mayo Clinic Proc., 2016; 91: 881–896MorgentalerA.ZitzmannM.TraishA.M.FoxA.W.JonesT.H.MaggiM.ArverS.AversaA.ChanJ.C.DobsA.S.HackettG.I.HellstromW.J.LimP.LunenfeldB.MskhalayaG.Fundamental concepts regarding testosterone deficiency and treatment: International expert consensus resolutionsMayo Clinic Proc.20169188189610.1016/j.mayocp.2016.04.00727313122Search in Google Scholar
Moskovic D.J., Araujo A.B., Lipshultz L.I., Khera M.: The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J. Sex. Med., 2013; 10: 562–569MoskovicD.J.AraujoA.B.LipshultzL.I.KheraM.The 20-year public health impact and direct cost of testosterone deficiency in U.S. menJ. Sex. Med.20131056256910.1111/j.1743-6109.2012.02944.x23035926Search in Google Scholar
Mulhall J.P., Trost L.W., Brannigan R.E., Kurtz E.G., Redmon J.B., Chiles K.A., Lightner D.J., Miner M.M., Murad M.H., Nelson C.J., Platz E.A., Ramanathan L.V., Lewis R.W.: Evaluation and management of testosterone deficiency: AUA guideline. J. Urol., 2018; 200: 423–432MulhallJ.P.TrostL.W.BranniganR.E.KurtzE.G.RedmonJ.B.ChilesK.A.LightnerD.J.MinerM.M.MuradM.H.NelsonC.J.PlatzE.A.RamanathanL.V.LewisR.W.Evaluation and management of testosterone deficiency: AUA guidelineJ. Urol.201820042343210.1016/j.juro.2018.03.11529601923Search in Google Scholar
Mulligan T., Frick M.F., Zuraw Q.C., Stemhagen A., McWhirter C.: Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int. J. Clin. Pract., 2006; 60: 762–769MulliganT.FrickM.F.ZurawQ.C.StemhagenA.McWhirterC.Prevalence of hypogonadism in males aged at least 45 years: The HIM studyInt. J. Clin. Pract.20066076276910.1111/j.1742-1241.2006.00992.x156944416846397Search in Google Scholar
Muraleedharan V., Marsh H., Kapoor D., Channer K.S., Jones T.H..: Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol., 2013; 169: 725–733MuraleedharanV.MarshH.KapoorD.ChannerK.S.JonesT.H..Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetesEur. J. Endocrinol.201316972573310.1530/EJE-13-032123999642Search in Google Scholar
Nieschlag E., Bouloux P.G., Stegmann B.J., Shankar R.R., Guan Y., Tzontcheva A., McCrary Sisk C., Behre H.M.: An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reprod. Biol. Endocrinol., 2017; 15: 17NieschlagE.BoulouxP.G.StegmannB.J.ShankarR.R.GuanY.TzontchevaA.McCrary SiskC.BehreH.M.An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadismReprod. Biol. Endocrinol.2017151710.1186/s12958-017-0232-y534139028270212Search in Google Scholar
Nieschlag E., Swerdloff R., Behre H.M., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morley J.E., Schulman C., Wang C., Weidner W., Wu F.C.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int. J. Androl., 2005; 28: 125–127NieschlagE.SwerdloffR.BehreH.M.GoorenL.J.KaufmanJ.M.LegrosJ.J.LunenfeldB.MorleyJ.E.SchulmanC.WangC.WeidnerW.WuF.C.Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendationsInt. J. Androl.20052812512710.1111/j.1365-2605.2005.00553.x15910536Search in Google Scholar
Ohlander S.J., Varghese B., Pastuszak A.: Erythrocytosis following testosterone therapy. Sex. Med. Rev., 2017; 61: 1038–1045OhlanderS.J.VargheseB.PastuszakA.Erythrocytosis following testosterone therapySex. Med. Rev.2017611038104510.1016/j.sxmr.2017.04.001569089028526632Search in Google Scholar
Pastuszak A.W., Badhiwala N., Lipshultz L.I. Khera M.: Depression is correlated with the psychological and physical aspects of sexual dysfunction in men. Int. J. Impot. Res., 2013; 25: 194–199PastuszakA.W.BadhiwalaN.LipshultzL.I.KheraM.Depression is correlated with the psychological and physical aspects of sexual dysfunction in menInt. J. Impot. Res.20132519419910.1038/ijir.2013.423466661Search in Google Scholar
Pugh P.J., Jones R.D., West J.N., Jones T.H., Channer K.S.: Testosterone treatment for men with chronic heart failure. Heart, 2004; 90: 446–447PughP.J.JonesR.D.WestJ.N.JonesT.H.ChannerK.S.Testosterone treatment for men with chronic heart failureHeart20049044644710.1136/hrt.2003.014639176816115020527Search in Google Scholar
Ramasamy R., Scovell J.M., Kovac J.R., Lipshultz L.I.: Testosterone supplementation versus clomiphene citrate for hypogonadism: An age matched comparison of satisfaction and efficacy. J. Urol., 2014; 192: 875–879RamasamyR.ScovellJ.M.KovacJ.R.LipshultzL.I.Testosterone supplementation versus clomiphene citrate for hypogonadism: An age matched comparison of satisfaction and efficacyJ. Urol.201419287587910.1016/j.juro.2014.03.08924657837Search in Google Scholar
Rao P.M., Kelly D.M., Jones T.H.: Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat. Rev. Endocrinol., 2013; 9: 479–493RaoP.M.KellyD.M.JonesT.H.Testosterone and insulin resistance in the metabolic syndrome and T2DM in menNat. Rev. Endocrinol.2013947949310.1038/nrendo.2013.12223797822Search in Google Scholar
Roberts C.K, Chen B.H., Pruthi S., Lee M.L.: Effects of varying doses of testosterone on atherogenic markers in healthy younger and older men. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2014; 306: R118–R123RobertsC.KChenB.H.PruthiS.LeeM.L.Effects of varying doses of testosterone on atherogenic markers in healthy younger and older menAm. J. Physiol. Regul. Integr. Comp. Physiol.2014306R118R12310.1152/ajpregu.00372.201324305063Search in Google Scholar
Saad F., Aversa A., Isidori A.M., Zafalon L., Zitzmann M., Gooren L.: Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocrinol., 2011; 165: 675–685SaadF.AversaA.IsidoriA.M.ZafalonL.ZitzmannM.GoorenL.Onset of effects of testosterone treatment and time span until maximum effects are achievedEur. J. Endocrinol.201116567568510.1530/EJE-11-0221318884821753068Search in Google Scholar
Santos M.R., Sayegh A.L., Groehs R.V., Fonseca G., Trombetta I.C., Barretto A.C., Arap M.A., Negrão C.E., Middlekauff H.R., Alves M.J.: Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure. Arq. Bras. Cardiol., 2015; 105: 256–264SantosM.R.SayeghA.L.GroehsR.V.FonsecaG.TrombettaI.C.BarrettoA.C.ArapM.A.NegrãoC.E.MiddlekauffH.R.AlvesM.J.Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failureArq. Bras. Cardiol.201510525626410.5935/abc.20150078459217426200897Search in Google Scholar
Sato Y., Tanda H., Kato S., Onishi S., Nakajima H., Nanbu A., Nitta T., Koroku M., Akagashi K., Hanzawa T.: Prevalence of major depressive disorder in self-referred patients in a late onset hypogonadism clinic. Int. J. Impot. Res., 2007; 19: 407–410SatoY.TandaH.KatoS.OnishiS.NakajimaH.NanbuA.NittaT.KorokuM.AkagashiK.HanzawaT.Prevalence of major depressive disorder in self-referred patients in a late onset hypogonadism clinicInt. J. Impot. Res.20071940741010.1038/sj.ijir.390155117460698Search in Google Scholar
Sharma R., Oni O.A., Chen G., Sharma M., Dawn B., Sharma R., Parashara D., Savin V.J., Barua R.S., Gupta K.: Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: A retrospective cohort study of the veterans administration database. Chest, 2016; 150: 563–571SharmaR.OniO.A.ChenG.SharmaM.DawnB.SharmaR.ParasharaD.SavinV.J.BaruaR.S.GuptaK.Association between testosterone replacement therapy and the incidence of DVT and pulmonary embolism: A retrospective cohort study of the veterans administration databaseChest201615056357110.1016/j.chest.2016.05.00727179907Search in Google Scholar
Stanworth R.D., Akhtar S., Channer K.S., Jones T.H.: The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study. Eur. J. Endocrinol., 2013; 170: 193–200StanworthR.D.AkhtarS.ChannerK.S.JonesT.H.The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-studyEur. J. Endocrinol.201317019320010.1530/EJE-13-070324165020Search in Google Scholar
Sussman E.M., Chudnovsky A., Niederberger C.S.: Hormonal evaluation of the infertile male: Has it evolved? Urol. Clin. North Am., 2008; 35: 147–155SussmanE.M.ChudnovskyA.NiederbergerC.S.Hormonal evaluation of the infertile male: Has it evolved?Urol. Clin. North Am.20083514715510.1016/j.ucl.2008.01.01018423236Search in Google Scholar
Taylor F., Levine L.: Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: Efficacy and treatment cost. J. Sex. Med., 2010; 7: 269–276TaylorF.LevineL.Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: Efficacy and treatment costJ. Sex. Med.2010726927610.1111/j.1743-6109.2009.01454.x19694928Search in Google Scholar
Vandenput L., Mellström D., Karlsson M.K., Orwoll E., Labrie F., Ljunggren Ö., Ohlsson C.: Serum estradiol is associated with lean mass in elderly Swedish men. Eur. J. Endocrinol., 2010; 162: 737–745VandenputL.MellströmD.KarlssonM.K.OrwollE.LabrieF.LjunggrenÖ.OhlssonC.Serum estradiol is associated with lean mass in elderly Swedish menEur. J. Endocrinol.201016273774510.1530/EJE-09-069620061331Search in Google Scholar
Vigen R., O’Donnell C.I., Barón A.E., Grunwald G.K., Maddox T.M., Bradley S.M., Barqawi A., Woning G., Wierman M.E., Plomondon M.E., Rumsfeld J.S., Ho P.M.: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 2013; 310: 1829–1836VigenR.O’DonnellC.I.BarónA.E.GrunwaldG.K.MaddoxT.M.BradleyS.M.BarqawiA.WoningG.WiermanM.E.PlomondonM.E.RumsfeldJ.S.HoP.M.Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levelsJAMA20133101829183610.1001/jama.2013.28038624193080Search in Google Scholar
Wang C., Nieschlag E., Swerdloff R., Behre H.M., Hellstrom W.J., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morales A., Morley J.E., Schulman C., Thompson I.M., Weidner W., Wu F.C. i wsp.: Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol., 2009; 55: 121–130WangC.NieschlagE.SwerdloffR.BehreH.M.HellstromW.J.GoorenL.J.KaufmanJ.M.LegrosJ.J.LunenfeldB.MoralesA.MorleyJ.E.SchulmanC.ThompsonI.M.WeidnerW.WuF.C.Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendationsEur. Urol.20095512113010.1016/j.eururo.2008.08.03318762364Search in Google Scholar
Wenker E.P., Dupree J.M., Langille G.M., Kovac J., Ramasamy R., Lamb D., Mills J.N., Lipshultz L.I.: The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. J. Sex. Med., 2015; 12: 1334–1337WenkerE.P.DupreeJ.M.LangilleG.M.KovacJ.RamasamyR.LambD.MillsJ.N.LipshultzL.I.The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone useJ. Sex. Med.2015121334133710.1111/jsm.1289025904023Search in Google Scholar
Wiehle R., Cunningham G.R., Pitteloud N., Wike J., Hsu K., Fontenot G.K., Rosner M., Dwyer A., Podolski J.: Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: Pharmacodynamics and pharmacokinetics. BJU Int., 2013; 112: 1188–1200WiehleR.CunninghamG.R.PitteloudN.WikeJ.HsuK.FontenotG.K.RosnerM.DwyerA.PodolskiJ.Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: Pharmacodynamics and pharmacokineticsBJU Int.20131121188120010.1111/bju.12363Search in Google Scholar
Wiehle R.D., Fontenot G.K., Michael M.S., Willett M.S., Garcia W.D., Podolski J.S.: Enclomiphene citrate stimulates serum testosterone in men with low testosterone within 14 days. J. Men’s Health, 2014; 11: 196–205WiehleR.D.FontenotG.K.MichaelM.S.WillettM.S.GarciaW.D.PodolskiJ.S.Enclomiphene citrate stimulates serum testosterone in men with low testosterone within 14 daysJ. Men’s Health20141119620510.1089/jomh.2014.0006Search in Google Scholar
Wiehle R.D., Fontenot G.K., Wike J., Hsu K., Nydell J., Lipshultz L., ZA-203 Clinical Study Group: Enclomiphene citrate stimulates testosterone production while preventing oligospermia: A randomized phase II clinical trial comparing topical testosterone. Fertil. Steril., 2014; 102: 720–727WiehleR.D.FontenotG.K.WikeJ.HsuK.NydellJ.LipshultzL.ZA-203 Clinical Study GroupEnclomiphene citrate stimulates testosterone production while preventing oligospermia: A randomized phase II clinical trial comparing topical testosteroneFertil. Steril.201410272072710.1016/j.fertnstert.2014.06.004Search in Google Scholar
World Health Organization Task Force on Methods for the Regulation of Male Fertility: Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril., 1996; 65: 821–829World Health Organization Task Force on Methods for the Regulation of Male FertilityContraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal menFertil. Steril.19966582182910.1016/S0015-0282(16)58221-1Search in Google Scholar
Wu F.C., Tajar A., Beynon J.M., Pye S.R., Silman A.J., Finn J.D., O’Neill T.W., Bartfai G., Casanueva F.F., Forti G., Giwercman A., Han T.S., Kula K., Lean M.E., Pendleton N. i wsp.: Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med., 2010; 363: 123–135WuF.C.TajarA.BeynonJ.M.PyeS.R.SilmanA.J.FinnJ.D.O’NeillT.W.BartfaiG.CasanuevaF.F.FortiG.GiwercmanA.HanT.S.KulaK.LeanM.E.PendletonN.Identification of late-onset hypogonadism in middle-aged and elderly menN. Engl. J. Med.201036312313510.1056/NEJMoa091110120554979Search in Google Scholar
Xu L., Freeman G., Cowling B.J., Schooling C.M.: Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med., 2013; 11: 108XuL.FreemanG.CowlingB.J.SchoolingC.M.Testosterone therapy and cardiovascular events among men: A systematic review and meta-analysis of placebo-controlled randomized trialsBMC Med.20131110810.1186/1741-7015-11-108364845623597181Search in Google Scholar
Zitzmann M., Mattern A., Hanisch J., Gooren L., Jones H., Maggi M.: IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J. Sex. Med., 2013; 10: 579–588ZitzmannM.MatternA.HanischJ.GoorenL.JonesH.MaggiM.IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 menJ. Sex. Med.20131057958810.1111/j.1743-6109.2012.02853.x22812645Search in Google Scholar